<DOC>
	<DOC>NCT02676284</DOC>
	<brief_summary>This was a prospective, open, non-comparative study in 36 subjects with rhizarthrosis comparing signs and symptoms before and after a single injection of DUROLANE SJ in the affected hand. Subjects were assessed pre-treatment and at 1, 3, and 6 months post-treatment.</brief_summary>
	<brief_title>Durolane SJ for Treatment of Rhizarthrosis</brief_title>
	<detailed_description>This study is associated with a post marketing commitment with the European Notified Body, BSI, to confirm DUROLANE SJ's effectiveness in rhizarthrosis.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Subjects of both sexes aged 18 to 75 years. Diagnosis of Grade IIIII rhizarthrosis in either hand, according to the criteria of Eaton and Littler. TMC joint pain lasting longer than 6 months and baseline pain value greater than or equal to 4 on the VAS scale (0 to 10) and less than 4 in the contralateral hand joint if there is pain. Anticoagulant medication Rheumatic disease involving the wrist, hand and fingers, such as rheumatoid arthritis or gout Active rheumatoid arthritis Previous surgery of the hand Systemic infectious processes Neoplastic disease Subjects with contraindications to hyaluronic acid Subjects with known hypersensitivity to hyaluronic acid or any of the components of the preparation under study Previous hyaluronic acid injections in the hand Subjects likely to miss the clinical followup visits Taking of analgesics 24 hours before scheduled clinical assessments Pregnant subjects Any condition that in the opinion of the physician recommends exclusion of the subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>